Figure 4
Figure 4. Function of Prdm16-deficient HSPCs. (A-C) Ratio between donor (300 Prdm16−/− or wt FL LSK cells (n = 4) (A), 500 Prdm16+/− or wt adult BM LSK cells (n = 9) (B), or 300 Prdm6+/− or wt adult BM LSKCD34−Flt3− cells (n = 4) (C) and competitor (0.5 × 106 T cell-depleted CD45.1+ or CD45.1+CD45.2+ B6 BM cells) cells among PB myeloid and B cells, and (C) thymic CD4+CD8+ double-positive and CD4−CD8− double-negative developing T cells, 10 to 15 weeks after transplantation into lethally irradiated B6.129F1 (CD45.2+) mice. *P < .01. (D) Representative example of donor (CD45.2+) and competitor (CD45.1+CD45.2+) reconstitution in doublet discriminated PB CD19+ B and Mac1+Gr1+ myeloid cells, and in thymic CD4−CD8− double-negative and CD4+CD8+ double-positive cells after competitive transplantation with wt or Prdm16+/− adult BM LT-HSCs.

Function of Prdm16-deficient HSPCs. (A-C) Ratio between donor (300 Prdm16−/− or wt FL LSK cells (n = 4) (A), 500 Prdm16+/− or wt adult BM LSK cells (n = 9) (B), or 300 Prdm6+/− or wt adult BM LSKCD34Flt3 cells (n = 4) (C) and competitor (0.5 × 106 T cell-depleted CD45.1+ or CD45.1+CD45.2+ B6 BM cells) cells among PB myeloid and B cells, and (C) thymic CD4+CD8+ double-positive and CD4CD8 double-negative developing T cells, 10 to 15 weeks after transplantation into lethally irradiated B6.129F1 (CD45.2+) mice. *P < .01. (D) Representative example of donor (CD45.2+) and competitor (CD45.1+CD45.2+) reconstitution in doublet discriminated PB CD19+ B and Mac1+Gr1+ myeloid cells, and in thymic CD4CD8 double-negative and CD4+CD8+ double-positive cells after competitive transplantation with wt or Prdm16+/− adult BM LT-HSCs.

Close Modal

or Create an Account

Close Modal
Close Modal